STOCK OPTIONS AND WARRANTS (Details 3) |
9 Months Ended |
|---|---|
|
Sep. 30, 2021
$ / shares
shares
| |
| Number exercisable | 818,006 |
| Warrants [Member] | |
| Number Outstanding | 15,000 |
| Weighted average remaining contractual life | 0.1 |
| Weighted average exercise price | $ / shares | $ 46.67 |
| Number exercisable | 15,000 |
| Weighted average remaining contractual life, Exercisable | 0.1 |
| 20.00 [Member] | Warrants [Member] | |
| Number Outstanding | 10,000 |
| Exercise Prices | $ / shares | $ 20.00 |
| Weighted average remaining contractual life | 0.2 |
| Weighted average exercise price | $ / shares | $ 20.00 |
| Number exercisable | 10,000 |
| Weighted average remaining contractual life, Exercisable | 0.2 |
| 100.00 [Member] | Warrants [Member] | |
| Number Outstanding | 5,000 |
| Exercise Prices | $ / shares | $ 100.00 |
| Weighted average remaining contractual life | 0.0 |
| Weighted average exercise price | $ / shares | $ 100.00 |
| Number exercisable | 5,000 |
| Weighted average remaining contractual life, Exercisable | 0.0 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, b No definition available.
|
| X | ||||||||||
- Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|